← All stocks

uniQure N.V.

QURE Net selling
CIK 0001590560 #1650 in the set updated 18 Sep 2026
Bought (120 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$80.76M
$245.49K on a plan · $42.95M straight out of an exercise
Sold at will
$37.56M
277 of 377 sales
Net
−$80.76M
−$37.56M against sales at will

By person

25 insiders · 377 transactions
35.2×

Matthew Kapusta holds 35.2 times base salary in stock. $23.83M of shares against $676.17K in salary for 2025.

Salary from the company's own proxy. The shares are what Matthew Kapusta last reported holding, valued at $45.89, the price Ordinary Shares was last bought or sold at on the open market here, on 2 Jul 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Kapusta Matthew C
CEO, Managing Director
$50.18M (138) scheduled
−$50.18M
519,227
0.7485%
$23.83M
+125.2%
Kuta Alexander Edward III
Executive VP, Operations
$5.14M (38) scheduled
−$5.14M
90,381
0.1303%
$4.15M
Gut Robert
Director
$4.96M (24) scheduled
−$4.96M
32,259
0.0465%
$1.48M
KLEMT CHRISTIAN
Chief Financial Officer
$4.79M (32)
−$4.79M
226,581
0.3266%
$10.40M
+885.1%
Kaye Jack
Director
$2.96M (18) scheduled
−$2.96M
25,996
0.0375%
$1.19M
Abi-Saab Walid
Chief Medical Officer
$2.65M (10) scheduled
−$2.65M
148,235
0.2137%
$6.80M
+120.6%
Soteropoulos Paula
Director
$1.92M (19)
−$1.92M
20,203
0.0291%
$927.12K
+26.3%
Astley-Sparke Philip
Director
$1.51M (14)
−$1.51M
9,946
0.0143%
$456.42K
−66.8%
Balachandran Madhavan
Director
$1.07M (13) scheduled
−$1.07M
43,254
0.0624%
$1.98M
Zelenkofske Steven
Chief Medical Officer
$888.72K (1)
−$888.72K
159,458
0.2299%
$7.32M
Petry Harald
Chief Scientific Officer
$846.06K (6) scheduled
−$846.06K
0
0.0000%
$0.00
Dolmetsch Ricardo
President, R&D
$590.56K (6)
−$590.56K
163,404
0.2356%
$7.50M
CALOZ PIERRE
Chief Operating Officer
$574.06K (9)
−$574.06K
115,707
0.1668%
$5.31M
O'Keefe Kylie
Chief Customer & Strat Officer
$431.23K (1)
−$431.23K
108,864
0.1569%
$5.00M
+3.7%
Potts Jeannette
Chief Legal Officer
$428.50K (6)
−$428.50K
133,246
0.1921%
$6.11M
SCHAFFER DAVID
Director
$371.73K (4)
−$371.73K
46,978
0.0677%
$2.16M
−12.0%
van Deventer Sander
EVP, Research & Product Dev.
$290.64K (4)
−$290.64K
102,512
0.1478%
$4.70M
+88.7%
Springhorn Jeremy P.
Director
$263.95K (10)
−$263.95K
43,251
0.0624%
$1.98M
Meek David D.
Director
$220.59K (9)
−$220.59K
39,747
0.0573%
$1.82M
POST LEONARD E
Director
$159.91K (6)
−$159.91K
35,494
0.0512%
$1.63M
Jacques Rachelle Suzanne
Director
$146.72K (5)
−$146.72K
33,903
0.0489%
$1.56M
Cantor Maria E
SVP, Investor Rel. & Comm.
$118.03K (1)
−$118.03K
92,439
0.1333%
$4.24M
+164.1%
Firuta Paul E
Chief Commercial Officer
$118.03K (1)
−$118.03K
93,817
0.1352%
$4.31M
+168.0%
Garen Jonathan
Chief Business Officer
$118.03K (1)
−$118.03K
93,638
0.1350%
$4.30M
+167.5%
McMillan Scott T.
Chief Operating Officer
$18.46K (1)
−$18.46K
20,432
0.0295%
$937.62K
+16,786%

Nothing of that kind in this period.

What was left out

Form 4 filings counted 393
Amendments (4/A) skipped 6
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 98
Sales at will 277
Transactions with no price 0
Shares from compensation/vesting 4,173,485
Sales filed before the plan box existed 213
History held since 31 Jan 2017